Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ludwig Röckl"'
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background Nivolumab is an anti-programmed cell death protein 1 antibody, typically used as cancer immunotherapy agent. Despite multiple clinical benefits it might cause autoimmune-related side-effects, often involving the endocrine system.
Externí odkaz:
https://doaj.org/article/146dd2221e804cf88b9a8f1a66e869fd
Publikováno v:
BMC Endocrine Disorders
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-6 (2021)
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-6 (2021)
Background Nivolumab is an anti-programmed cell death protein 1 antibody, typically used as cancer immunotherapy agent. Despite multiple clinical benefits it might cause autoimmune-related side-effects, often involving the endocrine system. To our kn